MOLECULAR CELLULAR BIOLOGY, Feb. 2011, p. 832â€“844                                                                          Vol. 31,  4
0270-7306/11/$12.00 doi:10.1128/MCB.00161-10
Copyright Â© 2011, American Society Microbiology. Rights Reserved.



          Bax Activation Engagement  Release                            BH3 Binding Site Bcl-xLäŒ¤
 F. Gautier,1,2 Y. Guillemin,1 P. F. Cartron,1 T. Gallenne,1 N. Cauquil,3 T. Le Diguarher,3 P. Casara,3
                F. M. Vallette,1 S. Manon,3 J.  Hickman,4 O. Geneste,4 P. Juin1*
 Centre Recherche CanceÂ´rologie Nantes Angers-UMR 892-INSERM/UniversiteÂ´ Nantes, Institut Recherche rapeutique          lâ€™UniversiteÂ´ Nantes, 8 Quai Moncousu, BP 70721, 44007 Nantes Cedex 1,1 partement Biologie Oncologique,
                Centre Lutte Contre le Cancer ReneÂ´ Gauducheau, Bd. J. Monod, 44805 Nantes-Saint Herblain,2
                      UMR5095 CNRS/UniversiteÂ´ Bordeaux, 21 Rue Camille Saint-SaeÂ¨ns, F-33077 Bordeaux,3
                        Institut Recherche Servier, Cancer Research Drug Discovery, 125 Chemin                                                Ronde, 78290 Croissy sur Seine,4 France
                      Received 9 February 2010/Returned modification 14 2010/Accepted 30 November 2010

             Bcl-2 homologues  Bcl-xL) promote survival sequestration â€œactivatorâ€? BH3           proteins  Puma), preventing directly activating Bax. assumed inhibition           interactions activators Bcl-xL prerequisite small molecules antagonize Bcl-xL           induce cell death. biological properties, described terphenyl-based alpha-helical peptidomimetic
          inhibitor Bcl-xL attest displacement Bax Bcl-xL critical. Terphenyl 14 triggers Bax-
          dependent Puma-independent cell death, disrupting Bax/Bcl-xL interactions affecting Puma/Bcl-xL
          interactions. cell-free assays, binding inactive Bax Bcl-xL, followed displacement Bcl-xL           terphenyl 14, produces mitochondrially permeabilizing Bax molecules.  peptidomimetic kills
          yeast cells express Bax Bcl-xL, uses Bax-binding Bcl-xL induce mammalian cell death.
          Likewise, ectopic expression Bax yeast mammalian cells enhances sensitivity Bcl-xL
          inhibitor, ABT-737, Bcl-xL present.  interaction Bcl-xL Bax paradoxically primes Bax
          time keeps Bax activity check, displacement Bax Bcl-xL triggers apoptotic
          signal itself. mechanism contribute clinical efficiency Bcl-xL inhibitors.


   Bcl-2 family interacting proteins plays major role           antiapoptotic function. contrast, molecular mecha-
regulating apoptosis. Antiapoptotic Bcl-2 homologs (e.g.,                   nism(s) BH3-binding activity Bcl-2 ho-
Bcl-2, Bcl-xL, Mcl-1) control survival progression              mologs, Bcl-xL, exerts control Bax exactly tumors sensitivity conventional therapy (34).               BH3 mimetics promote Bax-dependent apoptosis  preserve mitochondrial integrity opposing activity              main unclear. proapoptotic Bcl-2 family members Bax Bak,                    questions particularly apposite Bax display sequence conservation Bcl-2 homol-                 synthesized constitutively inactive form, cytosolic
ogy (BH) domains (BH1 -3) upstream                     peripherally associated mitochondria effectors, BH3 proteins (e.g., Bid Bad) (14, 41).              activated proapoptotic form exert cytotoxicity. mechanisms Bcl-xL counteracts toxicity                  Conformational changes leading exposure key func-
Bax particular importance human cancer cells,                  tional domains molecule required pro-
cause cells expression level Bcl-xL strongly                tein activated insert mitochondrial
correlates resistance chemotherapeutics (2),               membranes kill cells (reviewed references 21 Bax crucial apoptotic response diverse stimuli,               44). Bcl-2 homologs Bcl-xL, BH3-binding pro-
including BH3 proteins (45) (13) (4).                          teins, interfere process Bax â€œactivationâ€? requires
   certainties unknowns Bcl-xL pre-                 elucidation.
vents Bax activation activity. commonly agreed               subgroup BH3 proteins, Bim Puma, antiapoptotic function Bcl-2 homologs relies                  exerts direct Bax-activating properties epony-
ability hydrophobic grove, formed surface              mous BH3 domain (reviewed reference 22). BH1, -2, -3 domains, engage â?£-helical BH3 domains                thought BH3-binding activity Bcl-2 homologs pro- proapoptotic Bcl-2 family members (32). widely                motes survival great sequestering Bax â€œactivatorâ€?
accepted occupation BH3-binding site small-                 BH3 molecules. Consistent  ability diverse
molecule ligands, called BH3 mimetics, inhibit             Bcl-2 homologs maintain cell survival linked                                                                             physical engagement Bim Puma, induction
                                                                            cell death high-affinity BH3-mimetic inhibitor   * Corresponding author. Mailing address: CRCNA-UMR 892-                   Bcl-2 Bcl-xL ABT-737 shown coincide INSERM/UniversiteÂ´ Nantes, Institut Recherche rapeutique          inhibition interactions (8, 9, 11). demonstration lâ€™UniversiteÂ´ Nantes, 8 Quai Moncousu, BP 70721, 44007 Nantes
Cedex 1, France. Phone: 33-2-28-08-03-20. Fax: 33-2-28-08-02-04.
                                                                            functional hierarchy BH3 proteins,
E-mail: philippe.juin@univ-nantes.fr.                                       â€œBH3 activatorsâ€? (Bim Puma) acting downstream   äŒ¤
    Published ahead print 20 December 2010.                           â€œBH3 sensitizersâ€?  e., â€œBH3 ? proteins, 
                                                                      832
 VOL. 31, 2011                                                                             ACTIVATION Bax RELEASE Bcl-XL                                  833


Bad, bind prosurvival members Bcl-2 family                        media. ABT-737 synthesized previously described (30). Unless indicated, activate Bax directly) (16, 23), agreement                      reagents used study obtained Sigma.
                                                                                         Peptides recombinant proteins. Fluorescein isothiocyanate (FITC)-la- notion binding Bcl-2 homologs  Bcl-xL)                       beled nonfluorescent high-pressure liquid chromatography-purified Bid-BH3 BH3 activators  Puma) key event critically                       (EDIIRNIARHLAQVGDSMDR), Bad-BH3 (NLWAAQRYGRELRRMSDE
dictates cell fate. aforementioned hierarchy abso-                         FVDSFKK), Puma-BH3 (RGEEEQWAREIGAQLRRMADDL) Bax-BH3 (K
lute,  â€œBH3 activatorsâ€? required blown                        KLSECLKRIGDELDS), Bax-BH3 L63A (KKLSECAKRIGDELDS) pep-
                                                                                      tides obtained Sigma-Genosys (Cambridge, United Kingdom). apoptosis induction â€œBH3 sensitizers,â€œ nev-
                                                                                      preparation histidine-tagged  cell-free pulldown assays) glutathione
ertheless initiate apoptosis absence (42).                       S-transferase (GST)-fused  fluorescence polarization microinjection  account observations, proposed                        says) recombinant Bcl-xL (wild type G138A lacking 24 amino acids direct interaction Bcl-2 homologs Bax                             COOH terminus) described references 10 25, respectively.
involved determining cell survival (1). raises ques-                         Cell-free assays. Fluorescence polarization (FP) assays performed essen-
                                                                                      tially described reference 25. Fluorescent peptides (Bid-BH3, Bad-BH3, tion critical specific interaction                       Puma-BH3; 15 nM) GSTâ€“Bcl-xL (wild type G138A; 0.1 â?®M) mixed
regulation apoptosis. particular, understanding                         binding buffer (20 mM Na2HPO4 [pH 7.4], 50 mM NaCl, 1 mM EDTA, 0.05 
displacement Bax survival Bcl-2 homologs sufficient                        pluronic acid) titrations terphenyl 14 nonfluorescent peptides. promote cell death itself understanding Bax                             Fluorescence polarization measured using Fusion-Packard equipment. â€œactivatedâ€? conditions                               vitro synthesis quantification 35S-Met (Amersham, France)-labeled
                                                                                      Bax (35S-Bax) cDNAs using TNT coupled transcription/translation
cruitment â€œBH3 activatorsâ€? required, particularly                       (Promega, France) performed described previously (39). Cell-
understanding determinants BH3 mimetic toxicity.                            free protein binding experiments 35S-Bax tagged Bcl-xL (wild
   work presented addresses issues docu-                            type G138A indicated) performed essentially described menting biological properties previously described                           reference 28. Briefly, 35S-Bax (4 fmol) incubated tagged proteins (8
                                                                                      fmol) immobilized nickel-nitrilotriacetic acid (Ni-NTA) resin 50 â?®l binding
Bcl-xL antagonist. used cell-permeant terphenyl-based
                                                                                      buffer (142 mM KCl, 5 mM MgCl2, 10 mM HEPES [pH 7.4], 0.5 mM dithio-
peptidomimetic rationally designed mimic â?£-helical BH3                          threitol [DTT], 1 mM EGTA, 0.5 mM phenylmethylsulfonyl fluoride, domain based crystal solution structures                            mixture protease inhibitors) 30Â°C 2 h. resulting mixture BH3Bak/Bcl-xL complex (18, 43). treatment                             incubated additional hour 30Â°C absence presence cells compound inhibits Bax/Bcl-xL interactions                         indicated concentration terphenyl 14. Protein complexes centri-
                                                                                      fuged 13,000 â«» g 5 min 4Â°C washed times binding buffer.
fails interfere Puma/Bcl-xL interactions. com-                           resulting pellet, supernatant centrifugation 13,000 â«»
pound triggers Puma-independent, Bax-dependent cell death                             g, separated SDS-PAGE analyzed scanning relies Bax displacement Bcl-xL, evidenced                          PhosphorImager (Molecular Dynamics, France) followed quantification using following observations:   cell-free assays, initially inert                  IPLab gel program (Signal Analytics, Vienna, VA). indicated, super-
                                                                                      natants centrifugation added mitochondria (2.5 mg pro-
Bax gains proapoptotic activity interaction Bcl-xL
                                                                                      teins/ml) isolated rat liver, described reference 39, 37Â°C 1 h subsequent release Bcl-xL compound; (ii)                          40 â?®l standard import buffer (250 mM sucrose, 80 mM KCl, 10 mM MgCl2, 10
yeast cells express Bax Bcl-xL                       mM malic acid, 8 mM succinic acid, 1 mM ATP-Mg2â«¹, 20 mM morpholinepro-
proteins sensitive deleterious effects                        panesulfonic acid [MOPS], pH 7.5, reticulocyte lysate, 10  [vol/vol]), fol-
compound; (iii) induction mammalian cell death                          lowed centrifugation mitochondria. 35S-Bax (4 fmol) incubated 10 â?®M
                                                                                      terphenyl 14 1 h 30Â°C binding buffer absence tagged Bcl-xL
compound Bcl-xL-dependent process rescued                            incubated isolated rat liver mitochondria identical condi- wild-type Bcl-xL mutant Bcl-xL does                       tions. cytochrome c present mitochondrial supernatant
interact Bax. implies interaction Bax                      following given treatment analyzed Western blotting.
Bcl-xL, followed release survival protein                          cell-free immunoprecipitation assays 35S-Bax, radiolabeled Bax 
                                                                                      tagged Bcl-xL complexes prepared, treated terphenyl 14 (10
occupancy BH3-binding site, constitutes step (â€œtrap
                                                                                      â?®M), ABT-737 (1 â?®M), BH3 peptides (1 â?®M), isolated centrifugation releaseâ€?) process produce â€œactivatedâ€? Bax mole-                          described  resulting supernatants used immunoprecipita-
cules initiate cell death itself. Consistent                         tion assays using 6A7 2D2 anti-Bax antibody (4 â?®g), performed ABT-737 promote Bcl-xL-dependent Bax activation                           Catch Release V2.0 reversible immunoprecipitation (Upstate) ac- instances. Direct sustained interactions Bax                         cording manufacturerâ€™s recommendations. protocol used                                                                                       immunoprecipitation 0.8 fmol untreated 35S-Bax, 35S-Bax Bcl-xL critical cell survival, absence
                                                                                      treated 10 â?®M terphenyl 14 absence Bcl-xL, 35S-Bax BH3 activators.                                                                    incubated 30 min 37Â°C pH 4 prior neutralization pH 7.4,                                                                                       described reference 5. Immunoprecipitated radiolabeled proteins ana-
                                                                                      lyzed SDS-PAGE autoradiography described 
                        MATERIALS METHODS
                                                                                         Isolation mitochondria HeLa cells (cultured described     Reagents antibodies. following antibodies used: anti-Bcl-xL           performed subcellular fractionation. indicated HeLa cells scraped
antibody Epitomics (1018-1) immunoprecipitation Transduc-           using Teflon scraper centrifuged 1,000 â«» g 10 min 4Â°C. cell
tion Laboratories (610747) Western blotting, anti-Puma antibody Cal-         pellets washed twice ice-cold phosphate-buffered saline (PBS) biochem (Ab-1) Western blotting, anti-Bax 2D2  Western blotting           resuspended volume volume cell extraction buffer (CEB) (250 mM su-
immunoprecipitation) 6A7  immunoprecipitation) Beckman                   crose, 50 mM HEPES [pH 7.4], 50 mM KCl, 2 mM MgCl2, 1 mM dithiothreitol,
Coulter (731730 731731, respectively), anti-cytochrome c antibody            10 â?®M cytochalasin B, 1 mM EGTA, 1 tablet protease inhibitor). Cells R&D Systems (MAB897), anti-active caspase 3 antibody PharMingen                  allowed swell 30 min ice prior homogenization 50 strokes
(559565); anti-F1F0-ATPase subunit â?£ Molecular Probes  21350); anti-           ice-cold 2-ml glass Dounce homogenizer. Unbroken cells nuclei actin Chemicon (MAB1501R) immunocytochemistry. Horseradish               pelleted centrifugation 750 â«» g 10 min 4Â°C. Mitochondria oxidase-conjugated antibodies enhanced chemiluminescence reagents            collected resulting supernatants centrifugation 13,000 â«» g 15
obtained Bio-Rad (France) Santa Cruz. Fluorescent Alexa 488-             min 4Â°C. Mitochondrial pellets resuspended standard mitochondrial
Alexa 568-conjugated secondary antibodies obtained Molecular                buffer   prior determination protein concentration Probes. Terphenyl 14, synthesized described reference 18, systemati-        incubation indicated concentration terphenyl 14. cally prepared freshly dimethyl sulfoxide (DMSO) 100 mM concentration         cytochrome c present mitochondrial supernatant mitochondrial
prior dilution appropriate concentrations indicated buffers culture   fraction following given treatment analyzed Western blotting.
 834       GAUTIER ET AL.                                                                                                                             MOL. CELL. BIOL.

   Mammalian cell culture. Human colorectal cancer cells lines derived            e., DsRed-positive) cells performed using Zeiss Axiovert 200-M inverted
HCT116 (p21â«º/â«º, p21â«º/â«º Pumaâ«º/â«º, p21â«º/â«º Baxâ«º/â«º) kindly provided             fluorescence microscope.
B. Vogelstein. cells grown complete McCoy medium previously             Yeast assays. Yeast expressing galactose-inducible wild-type untagged Bax,
described (45). HeLa cells cultured RPMI 1640 supplemented 10            Bcl-xL, obtained transforming wild-type haploid strain
fetal calf serum, penicillin (100 U/ml), streptomycin (100 â?®g/ml), 2 mM           W303-1B (mata ade2 his3 leu2 trp1 ura3) vectors pYES3/Bax glutamine. Simian virus 40 (SV40) large-T-antigen-immortalized wild-type          pDP83A/Bcl-xL, express corresponding cDNA control Bcl-xLâ«º/â«º mouse embryonic fibroblasts (MEFs), kindly provided D. Huang,            GAL1/10 promoter, TRP1 URA3 yeast selection markers, respec- cultured Dulbeccoâ€™s modified Eagle medium (DMEM) supplemented                 tively (3). 10  fetal calf serum, penicillin (100 U/ml), streptomycin (100 â?®g/ml),          Cells grown aerobically 28Â°C semisynthetic medium containing
2 mM glutamine.                                                                       0.17  yeast nitrogen base (Difco), 0.1  potassium phosphate, 0.5  ammonium
   Mammalian cell assays. Recombinant lentivirus (shScr shBcl-xL, target-         sulfate, 0.2  Drop-Mix, 0.01  auxotrophic requirements, 2  DL-lactate
ing nucleotides 58 76 human Bcl-xL) engineered, produced,              nonfermentable carbon source (pH 5.5). Cultures diluted cell
titrated previously described (11). multiplicity infection 5 used,     density 1 â«» 106 cells/ml medium supplemented 1  galactose experiments performed 3 days infection.                        induce expression proteins 8 h.
   Transient transfection lentivirus-treated HeLa  HCT116 p21â«º/â«º                   immunoprecipitation experiments, cells diluted, protein induc-
Pumaâ«º/â«º) plasmids expressing short hairpin RNA (shRNA)-resistant Bcl-xL          tion, cell density 1 â«» 106 cells/ml medium  e., galactose)
cDNAs performed using Lipofectamine 2000 reagent (Sigma-Aldrich)              drugs (100 â?®M terphenyl 14) mock (DMSO plus 0.02  Tween 20) according manufacturerâ€™s instructions. shRNA-resistant cDNAs ob-          added. hours later, cells (5 ml culture) washed twice 10 mM
tained introducing silent point mutations region targeted   Tris-maleate (pH 6.7) containing 0.4 M mannitol, 2 mM EGTA, antiproteases shRNA, nucleotides 63, 67, 68, 75 (uppercase letters), replacing       (Complete; Roche), antiphosphatases (Phostop; Roche) broken original sequence, aaaggAtacAGctggagTc, aaaggGtacTCctggagCc. Cells            glass beads (3 min). unbroken cells sedimented (900 â«» g, 10 min), 80  confluence 1 12 plate treated overnight Lipo-         supernatant added 10â«» immunoprecipitation (IP) buffer (IP50; Sigma)
fectamine mixed 1 â?®g pCMV-shresBcl-xL, pCMV-shresBcL-xL                incubated 4Â°C 40 min. Anti-Bax antibody (mouse monoclonal 2D2;
G138A, pCMV-shresBcL-xL L90A, pCMV-shresBcL-xL âŒ¬TM (lacking 23                    Sigma) added (2 â?®g/ml), immunoprecipitation overnight amino acids C terminus), pCMV vector Opti-MEM                4Â°C. Protein G Sepharose beads added incubated 6 h. Beads reduced serum medium. Transfected cells washed left additional        washed 6 times incubated 25 â?®l Laemmli buffer 5 min 90Â°C.
24 h complete medium prior indicated treatment, Western blot analysis       Samples separated SDS-PAGE, transferred polyvinylidene difluoride cell death assays. Transient transfection lentivirus-treated HeLa cells   (PVDF), immunoblotted anti-Bax (N20; Santa-Cruz) anti-Bcl-x (BD
plasmid expressing Bax cDNA performed essentially described              Transduction Laboratories) rabbit polyclonal antibodies. Immunoblots 
using cells grown 80  confluence 1 6 plate transfected      vealed ECLâ«¹ (GE Healthcare). Nonsaturated films 0.2 â?®g pCMV-Bax.                                                                   scanned quantified using ImageJ software program.
   Stable knockdown Bax Bcl-xL HeLa cells performed using                  cell viability assays, cells diluted cell density 1 â«» 106 cells/ml
pSilencer2.1 plasmids contain short hairpin RNA targeted oligonucleo-         protein induction incubated presence   compounds tides 392 400 human BAX oligonucleotides 578 598 human              additional 12 h medium, cell density assessed.
BCL-X, introduced pSilencer2.1-Hygro plasmid previously described
(26). HeLa cells expressing corresponding plasmids negative-control
pSilencer2.1-Hygro-SCR plasmid obtained electroporation followed                                              RESULTS
selection hygromycin (100 â?®g/ml). Functional assays performed absence hygromycin using bulk selected cells avoid clonal bias.             BH3-mimetic terphenyl 14 triggers Bax-dependent cell
   HeLa HCTT116 cells manipulated described treated         death independently BH3 activator Puma. tool appropriate time needed concentrations terphenyl 14, ABT-737,          study inhibition BH3-binding site Bcl-xL DMSO carrier  DEVDase activity cellular lysates measured described reference 6. Cell death evaluated using trypan blue
                                                                                      trigger Bax activation, used synthetic small molecule
staining procedure. immunocytochemical analysis, cells grown glass cov-        described Kutzki colleagues, terphenyl 14, mim-
erslips fixed stained previously described (6). Coimmunoprecipita-        ics â?£-helical BH3 domain (18). Nuclear magnetic resonance
tion assays performed indicated treatments using 4 â?®g           (NMR) spectroscopy shown terphenyl 14 targets indicated antibody 500 â?®g protein lysates CHAPS buffer (HEPES [10
                                                                                      helical, BH3 binding area surface Bcl-xL (43). Fluo-
mM], NaCl [150 mM], CHAPS [1 ] [pH 7.4]) Catch Release
V2.0 reversible immunoprecipitation (Upstate), according manu-          rescence polarization assays using recombinant Bcl-xL fused facturerâ€™s recommendations.                                                           GST, previously described (25), confirmed terphenyl 14
   Short-term knockdown Bcl-xL Mcl-1 HeLa cells performed             inhibited binding diverse BH3 peptides (derived transient transfection validated siBcl-xL siMcl-1 nucleotides control    Bid, Bad, Puma) Bcl-xL dose-dependent manner
small interfering RNAs (siRNAs) (Ambion) using HiPerfect transfection
                                                                                      (Fig. 1 Table 1), agreement notion reagent (Qiagen 301705) according manufacturerâ€™s instructions. func-
tional assays, 5 â«» 104 cells seeded 9-mm dishes 24 h prior transfection.   bona fide BH3 mimetic.
Nucleotides (0.6 â?®l, 20 â?®M) incubated HiPerfect reagent (6 â?®l)         investigate biological effects terphenyl 14, 10 min room temperature 100 â?®l serum-free RPMI medium               treated human colorectal cancer cell line HCT116 p21â«º/â«º
added cell complete medium final nucleotide concentration 5 nM.        compound. cells rely expression Cells incubated nucleotides 48 h  siBcl-xL) 24 h  siMcl-1)
prior subsequent treatment terphenyl 14 ABT-737. Western blot
                                                                                      Bcl-xL maintain survival culture (11). experiments, procedure employed using 2 â«» 105 cells seeded            constitutive expression BH3 activator Puma,
35-mm dishes 24 h transfection corresponding siRNA           like Bax, bound Bcl-xL cells. shown nucleotides.                                                                          Fig. 2A, treatment HCT116 p21â«º/â«º cells terphenyl 14
   Transient transfection Bcl-x knockout MEFs plasmids encoding Bcl-xL
                                                                                      (50 100 â?®M) induced cell death. process Bax
wild type G138A plasmid encoding red fluorescent protein
DsRed performed using Lipofectamine 2000 reagent. Briefly, 105 cells          dependent judged resistance corresponding seeded 1 24 plate prior overnight incubation           HCT116 p21â«º/â«º Baxâ«º/â«º cells treatments. Surpris-
Lipofectamine mixed 0.2 â?®g pDs-Red 0.8 â?®g pCMV-Bcl-xL,          ingly, HCT116 p21â«º/â«º Pumaâ«º/â«º cells sensitive pa-
pCMV-BcL-xLG138A, pCMV vector Opti-MEM reduced                      rental cells terphenyl 14. inferred lack effect
serum medium. Transfected cells washed left additional
24 h complete DMEM. Immunocytochemical Western blotting indicated
                                                                                      Puma expression response HCT116 p21â«º/â«º cells expression ectopic Bcl-xL Bcl-xL G138 transfected Bcl-xâ«º/â«º     terphenyl 14 relied inability compound liber-
MEFs comparable (data shown). Morphological analysis fluorescent          ate sufficient Puma protein survival proteins.
 VOL. 31, 2011                                                                          ACTIVATION Bax RELEASE Bcl-XL                         835




  FIG. 1. Inhibition Bcl-xL binding BH3 peptides terphenyl 14 (Terph. 14). Fluorescence polarization-based competitive binding assays
using fluorescein-labeled Bid-BH3, Bad-BH3, Puma-BH3 (15 nM) complex Bcl-xL  GST fusion protein; 100 nM) shown terphenyl 14 respective nonfluorescent peptides indicated concentrations (C). Data means (â«¾ SEM) results 3 independent
experiments. mP, milli-polarization level.



Consistent  treatment cells terphenyl 14 impact Puma/Bcl-xL interactions, evaluated coimmunoprecipitation assays (Fig. 2B). 
trast, terphenyl 14 significantly displaced endogenous Bax Bcl-xL, agreement previous report (43). note, coimmunoprecipitation assays performed cell lysates
obtained using CHAPS, detergent does induce overt
modifications Bax conformation itself (15).
   Terphenyl 14 cooperates Bcl-xL promote Bax activa-
tion cell-free assays. follows experiments terphenyl 14 induction Bax- dependent cell death oc-
curs recruitment BH3 activator Puma, terphenyl 14 displace Bcl-xL, conditions Bax displaced Bcl-xL. investigated displacement Bax Bcl-xL terphenyl 14 directly promote cell death.
   investigated terphenyl 14 able pro-
mote cell-free activation Bax presence target
Bcl-xL absence direct BH3 activators using pub-
lished methods (4, 28). assays, vitro-translated ra-
diolabeled (IVTR) Bax molecules used. molecules essentially inert isolated mitochondria. â€œinac-
tiveâ€? IVTR Bax molecules interact Bcl-xL significantly, efficiently IVTR Bax molecules â€œactivatedâ€? coincubation Bid (28). speci-
ficity interactions, evaluated cell-free
pulldown assays using recombinant tagged Bcl-xL, 

                                                                                       FIG. 2. Role Puma Bax cell death induction HCT116
    TABLE 1. Effect terphenyl 14 BH3 binding Bcl-xLa                       p21â«º/â«º cells terphenyl 14.   Effect terphenyl 14 viability.
                                        IC50 (â?®M)                               Parental, Bax knockout, Puma knockout HCT116 p21â«º/â«º cells                                                                                     treated indicated concentration terphenyl 14 24 h prior
 Peptide        BcI-xL/        BcI-xL/                                BcI-xL/       measurement cell viability. Data means (â«¾ SEM) results
                                            BcI-xL(G138A)/Fluo
               Fluo Bid-      Fluo Bad-                                Fluo         3 independent experiments. (B) Effect terphenyl 14 Bax/
                                                 Bad-BH3
                 BH3             BH3                                 Puma-BH3       Bcl-xL Puma/Bcl-xL interactions. HCT116 p21â«º/â«º cells Terph. 14      1.74 â«¾ 0.69   6.36 â«¾ 2.45         6.94 â«¾ 1.05          3.2 â«¾ 0.39    treated terphenyl 14 (100 â?®M) (Ter. 14) treated (Unt.) Bid-BH3        0.66 â«¾ 0.20       ND                  ND                  ND         24 h, resulting cell lysates immunoprecipitated  P.) Bad-BH3            ND        0.27 â«¾ 0.02         0.17 â«¾ 0.01             ND         anti-Bcl-xL antibody. Bcl-xL, Bax, Puma present total extracts
Puma-BH3           ND            ND                  ND              0.25 â«¾ 0.01    immunoprecipitated fractions analyzed immunoblotting
                                                                                       (W.B.). Bax Puma coimmunoprecipitated      Interaction fluorescent (Fluo) peptides Bcl-xL (wild type G138A)
                                                                                    Bcl-xL condition evaluated densitometric analysis presence terphenyl 14 (Terph. 14) unlabeled peptides analyzed fluorescence polarization. IC50, concentration required displace 50    normalized protein coimmunoprecipitated fluorescent BH3 peptides (15 nM) bound 100 nM GST-fused Bcl-xL.              Bcl-xL untreated cells. Data means (â«¾ SE) results Bcl-xL(G138A) does bind Bid-BH3. Data means (â«¾ SEM) results         independent experiments. P values assessed using Student
3 independent experiments. ND, determined.                                      t test.
 836     GAUTIER ET AL.                                                                                                          MOL. CELL. BIOL.




   FIG. 3. Terphenyl 14 cooperates Bcl-xL promote cell-free Bax activation.  B) Effect terphenyl 14 cell-free binding Bax Bcl-xL.   vitro-translated radiolabeled Bax (4 fmol) incubated indicated tagged Bcl-xL recombinant proteins (8 fmol). bound protein complexes centrifuged, presence free 35S-Bax resulting supernatant (F.) 35S-Bax bound Bcl-xL
following additional washes (B.) analyzed SDS-PAGE autoradiography PhosphorImager. Autoradiograms representative independent experiments shown. Input, 4 fmol untreated 35S-Bax loaded illustrative purposes. average quantity Bax
bound complexes (mean â«¾ SE results independent experiments) evaluated expressed percentage initial 35S-Bax (n , nonapplicable). wt, wild type. (B) Bcl-xL wild type/35S-Bax complexes left untreated treated 10 â?®M
terphenyl 14. presence initial complexes (lane 1) supernatant resulting mock treatment (lane 2) terphenyl treatment (lane 3) tagged Bcl-xL 35S-Bax analyzed Western blotting using anti antibody (34660 Qiagen) autoradiography, respectively. Data representative independent experiments shown. average quantity Bax displaced complexes 10 â?®M terphenyl 14 (mean â«¾ SE results independent experiments), expressed percentage 35S-Bax
present initial complexes, indicated. (C) Effect terphenyl 14 Bax-induced mitochondrial permeabilization presence Bcl-xL. Left, 35S-Bax (4 fmol) incubated tagged-Bcl-xL (8 fmol) prior addition terphenyl 14. bound protein complexes centrifuged, presence 35S-Bax resulting supernatant (free 35S-Bax) pellet following additional washes
(Bcl-xL-bound 35S-Bax) analyzed SDS-PAGE autoradiography PhosphorImager. Data representative independent
experiments shown. Right, 35S-Bax (4 fmol) bound tagged Bcl-xL treated terphenyl 14 prior incubation rat liver
mitochondria (100 â?®g) 1 h 37Â°C. presence cytochrome c supernatant following centrifugation mitochondria analyzed Western blotting. indicated, terphenyl 14 (10 â?®M) directly added 4 fmol 35S-Bax absence Bcl-xL prior incubation isolated mitochondria. Western blots representative independent experiments shown. (D) Effect terphenyl 14 Bax conformation presence Bcl-xL. 35S-Bax subjected indicated treatment prior immunoprecipitation 2D2 6A7 anti-Bax antibody.
1, untreated 35S-Bax; 2, 35S-Bax treated 10 â?®M terphenyl 14 absence Bcl-xL; 3, 35S-Bax preincubated pH 4; 4, 35S-Bax preincubated tagged Bcl-xL released Bcl-xL 10 â?®M terphenyl 14. Data representative independent experiments shown.



strongly underscored fact abrogated                cytochrome c release unless prebound Bcl-xL (Fig. G138A mutation Bcl-xL (Fig. 3A).                                 3C). implies active contribution Bcl-xL acti-
   cell-free pulldown assays, terphenyl 14 disrupted              vation Bax mitochondrial permeabilizing activity terphe-
teraction IVTR Bax recombinant tagged Bcl-xL                    nyl 14. test determine (Fig. 3B) dose-dependent manner (Fig. 3C). confirms               process accompanied change Bax conformation, compound exerts direct inhibitory effect Baxâ€“                used previously reported cell-free immunoprecipitation 
Bcl-xL interactions. Bax molecules displaced                     say, devoid isolated mitochondria, using conformation-
Bcl-xL terphenyl 14 exhibited mitochondrial permeabilizing               specific 6A7 monoclonal anti-Bax antibody (15, 28). Binding properties, judged ability induce cytochrome c               antibody Bax indicates change Bax conformation
release added rat liver mitochondria (Fig. 3C),                notably, induced incubation IVTR Bax permeabilized BH3 peptides unless exogenous Bax                  activator BH3 peptides  Bid-BH3) enhance added (4). note, Bcl-xL combined terphenyl 14 (10                Bax mitochondrial activity (4). contrast, native
â?®M) unable induce cytochrome c release absence                IVTR Bax Bcl-xL-bound IVTR Bax immunoreacted Bax (data shown), indicating terphenyl 14, pre-              antibody (4). shown Fig. 3D, 6A7 antibody
viously reported BH3 peptides, does convert Bcl-xL             immunoreacted IVTR Bax acidification  posi- protein innate permeabilizing properties (19, 28).                   tive control Bax activation [5]) IVTR Bax    assays, initial IVTR Bax,             displaced Bcl-xL 10 â?®M terphenyl 14 presence 10 â?®M terphenyl 14, insufficient induce              IVTR Bax terphenyl 14 added absence  VOL. 31, 2011                                                            ACTIVATION Bax RELEASE Bcl-XL                      837


Bcl-xL. contrast, 2D2 antibody, recognizes Bax
regardless conformation, immunoprecipitated IVTR Bax conditions tested (Fig. 3D). Analysis 2D2-immu-
noprecipitated Bax nondenaturing conditions showed,  IVTR Bax displaced Bcl-xL terphenyl 14 form homodimers solution, 
ported feature â€œactivatedâ€? Bax molecules (data shown).  step process initially inactive Bax binds Bcl-xL released Bcl-xL terphenyl 14
BH3 mimetic produces activated Bax molecules cell-free
assays.
   Yeast cells expressing Bax Bcl-xL sensitive ter-
phenyl 14. confirm â€œtrap releaseâ€? mechanism
described sufficient initiate cell death, used yeast
cells. Yeast express recognized Bcl-2 family proteins. tolerate expression length untagged wild-type hu-
man Bax undergo cell death express Bax vari-
ants carry mutations critically affect protein 
formation express wild-type Bax BH3 activators (3, 11, 33, 40). analyzed expression Bax Bcl-xL context sufficient install sensitivity terphenyl 14, employing yeast strains express galactose-inducible Bax, Bcl-xL,  Untagged
wild-type Bax used induction         FIG. 4. Expression Bax Bcl-xL renders yeast cells sensitive
detectable impact yeast viability itself (33).                  terphenyl 14.  B) Effect terphenyl 14 treatment                                                                       Bax/Bcl-xL interactions yeast. indicated strains grown,
   coexpression Bax Bcl-xL lead substantial          Bax Bcl-xL expression induced galactose prior interaction proteins, judged coimmuno-            treatment terphenyl 14 (100 â?®M) mock treatment (DMSO
precipitation experiments (Fig. 4A). Treatment yeast cells         plus 0.02  Tween 20) additional 6 h, followed immuno-
coexpressing Bax Bcl-xL terphenyl 14 (100 â?®M)             precipitation anti-Bax antibodies Western blotting (WB)
hibited Bax/Bcl-xL interactions (assayed coimmunoprecipi-          resulting immunoprecipitates  . amounts Bcl-xL                                                                       Bax immunoprecipitated anti-Bax antibodies tation experiments) (Fig. 4A B). significant decrease        evaluated densitometric analysis. Bcl-xL/Bax ratio  viability yeast expressing Bax Bcl-xL     malized 1 mock conditions experiment. Data expressing observed condi-           means (â«¾ SEM) results independent experiments (B).
tions (Fig. 4C).                                                      (C) Effect terphenyl 14 viability yeast cells expressing
                                                                      Bax, Bcl-xL,  indicated strains grown pres-
   Terphenyl 14 requires Bcl-xL trigger Bax-mediated mito-         ence galactose, cell density measured chondrial permeabilization cell death. analyzed           indicated yeast strains 12 h treatment terphenyl 14 (100 cooperation Bcl-xL terphenyl 14            â?®M). expressed percentage density measured liberate activated Bax, analyzed assays,         corresponding mock-treated samples. Data means (â«¾ SEM) triggered mammalian cells Bcl-xL contributes Bax         results 8 independent experiments. P values (â´±, P â¬? 0.005)
                                                                      assessed using Student t test.
activation induced terphenyl 14. previously published HCT116 p21â«º/â«º cells undergo cell death Bcl-xL
depletion RNA interference unless Puma expression di-
minished (11). used HCT116 p21â«º/â«º Pumaâ«º/â«º cells               compared results control cells (data shown). Like- downregulated Bcl-xL expression previously pub-            wise, human glioblastoma cells depleted Bax Bcl-xL
lished approach using recombinant lentivirus expresses         stable expression pSilencer plasmids (26) green fluorescent protein (GFP) short hairpin         resistant induction cell death terphenyl 14 (data RNA (shRNA) targeting Bcl-xL (shBcl-xL) (11). Bcl-xL               shown). Immunohistochemical analysis revealed Bcl-xL
pleted cells cells infected control lentivirus         knockdown HeLa cells, akin Bax knockdown HeLa cells,
treated terphenyl 14. shown Fig. 5A, downregu-         resistant induction cytochrome c release terphe-
lation Bcl-xL reduced cell death induced terphenyl 14.          nyl 14 treatment (Fig. 5B). Subcellular fractionation analysis
   investigate role played Bcl-xL terphenyl      indicated, agreement previous report (38), Bax
14-induced cell death, used HeLa cells Bax         present mitochondria isolated control HeLa cells. Bcl-xL expression selectively downregulated sta-        Bax molecules â€œperipherallyâ€? associated
ble expression recombinant plasmids express shRNA             mitochondria detached mitochon-
(HeLa pSilencer Bax pSilencer Bcl-xL cells, respectively;         drial fraction following alkaline treatment (Fig. 5C). Addition
note Bcl-xL reduction HeLa cells maintained          terphenyl 14 control HeLa cells induced insertion culture numerous passages). Terphenyl 14 treatment         mitochondrially localized Bax mitochondrial membranes,
control cells inhibited interactions Bax Bcl-xL,      indicated increase alkaline-resistant terphenyl 14 cytotoxic HeLa cells            mitochondrial Bax (Fig. 5C). Terphenyl 14 treatment induced Bax Bcl-xL expression selectively downregulated         Bax insertion mitochondrial membranes effi-
 838     GAUTIER ET AL.                                                                                                     MOL. CELL. BIOL.




   FIG. 5. Bcl-xL involved induction mitochondrial Bax activity terphenyl 14.   Bcl-xL contributes cell death induction terphenyl 14 HCT116 p21â«º/â«º Pumaâ«º/â«º cells. HCT116 p21â«º/â«º Pumaâ«º/â«º cells infected control recombinant lentivirus (shScr) recombinant lentivirus expressing short hairpin targeting Bcl-xL (shBcl-xL) treatment terphenyl 14 (100 â?®M). hours later, cell death assessed described legend Fig. 2. Data means (â«¾ SEM) results 3 independent
experiments. (B) Bcl-xL required Bax-dependent induction cytochrome c (cyt c) release caspase 3 (casp3) activation terphenyl
14. Immunostaining cytochrome c active caspase 3 HeLa cells expressing control plasmid (SCR), pSilencer Bax (shBax), pSilencer BCL-X (shBcl-x) treated terphenyl 14 (100 â?®M) 18 h performed. percentages cells exhibiting
mitochondrial cytochrome c release active caspase 3 following treatment indicated. Data shown means (â«¾ SE) results 4 independent experiments. (C) Bcl-xL required efficient induction mitochondrial Bax insertion terphenyl 14. indicated HeLa
cells treated terphenyl 14 (100 â?®M) 18 h. Mitochondria isolated left untreated treated alkaline
carbonate. amounts mitochondrion-bound (untreated mitochondria) membrane-inserted (alkaline-treated mitochondria) Bax F1 ATPase  control mitochondrial membrane protein) analyzed Western blotting. Bax inserted mitochondrial membranes  e., alkaline resistant) condition evaluated densitometric analysis normalized protein inserted mitochondria control cells treated terphenyl 14. Data means (â«¾ SE.) results independent
experiments. P values assessed using Student t test. (D) Mitochondria HeLa cells intrinsically sensitive induction Bcl-xL-dependent cytochrome c release terphenyl 14. Mitochondria isolated indicated HeLa cells incubated terphenyl
14 standard mitochondrial buffer 1 h 37Â°C. amounts cytochrome c present mitochondrial fraction mitochondrial supernatant (â€œreleasedâ€?) analyzed Western blotting. Data representative independent experiments shown. F1 ATPase used control mitochondrial membrane protein.



ciently Bcl-xL knockdown cells (Fig. 5C). strong           peptidomimetic proteins mitochondria,
agreement notion Bcl-xL-dependent Bax mito-                Bax/Bcl-xL complexes reported reside (47).
chondrial insertion critical induction mitochon-           confirm  directly incubated terphenyl 14 drial permeabilization terphenyl 14.                                  mitochondria isolated HeLa cells. Terphenyl 14 
   Intriguingly, terphenyl 14 treatment induced modest              duced cytochrome c release mitochondria isolated
changes amounts Bax present mitochondrial                control HeLa cells detectable effect cytosolic fractions (Fig. 5C data shown). sug-              concentrations used mitochondria isolated gests terphenyl 14-induced, Bax-dependent mitochon-                 Bax knockdown, Bcl-xL knockdown cells (Fig. 5D).
drial permeabilization essentially ensues effect               permeability mitochondria HeLa cells
 VOL. 31, 2011                                                           ACTIVATION Bax RELEASE Bcl-XL                    839


exhibits inherent sensitivity terphenyl 14 relies        ecules Bcl-xL. contrast, negative-control mutant Bax- Bax  importantly, Bcl-xL.                        BH3 peptide (L63A) unable release Bax molecules    ability Bcl-xL cooperate terphenyl 14 pre-      Bcl-xL (Fig. 7A).
vented single mutation Bcl-xL abrogates inter-         Second, treated yeast cells express Bax Bcl-xL
action Bax. investigated ability      concentrations ABT-737 (20 â?®M) inhibited Bax/
Bcl-xL interact Bax required Bcl-xL mediate        Bcl-xL interactions (Fig. 7B). treatment significantly af-
terphenyl 14-induced Bax activation, using G138A mutant          fected viability yeast cells expressed Bcl-xL. interaction mutant Bax abrogated      Bax Bcl-xL, indicating  case terphenyl single mutation BH1 domain Bcl-xL (29, 31) (Fig.      14, disruption Bax/Bcl-xL interactions ABT-737 suffices 2A). Fluorescence polarization assays indicated mu-        initiate cell death.
tant capable binding Bad-BH3 terphenyl            explored ABT-737 trigger Bcl-xL 
14 disrupted interaction (Table 1).  Bcl-xL G138A       pendent activation Bax mammalian cells. used HeLa
deficient interaction Bax interac-      cells transfected untagged Bax conditions
tion terphenyl 14.                                              ectopic Bax expression did promote cell death
   HeLa cells depleted Bcl-xL lentivirus ap-          itself (Fig. 7C). transfection sufficient
proach described  prior reintroduction Bcl-xL vari-      sensitize cells infected control lentivirus
ants transient transfection plasmids express        (scr) induction cell death ABT-737. effect corresponding cDNA, modified shRNA target sequence            dependent endogenous Bcl-xL, observed order make resistant inhibition RNA interference.     cells infected shBcl-xL lentivirus (Fig.
Wild-type Bcl-xL restored sensitivity Bcl-xL knockdown        7C). Reintroduction wild-type Bcl-xL (using shRNA-resis-
HeLa cells terphenyl 14, G138A mutant did (Fig.       tant cDNA) restored sensitivity Bcl-xL knockdown cells,
6A). contrast, variant Bcl-xL lacking 23 amino acids      case G138A mutant (Fig. 7C). C terminus (Bcl-xL âŒ¬TM) unable localize            Taken  data strongly suggest ABT-737 uses
mitochondria (32) (immunohistochemical analysis confirmed            Bax-binding Bcl-xL molecules promote death cells cytosolic localization deletion mutant; data         enhanced Bax expression.
shown) variant carrying single mutation BH3              confirm ABT-737 promote Bcl-xL-dependent
domain Bcl-xL (Bcl-xL L90A) abrogates proapop-           cell death, analyzed role Bcl-xL play cell
totic activity Bcl-xS, prodeath activity     death induction ABT-737 HeLa cells depleted domain (7), efficient wild-type Bcl-xL. Similar results   Mcl-1, Bcl-2 homolog targeted ABT-737 (30). obtained HCT116 p21â«º/â«º Pumaâ«º/â«º cells (Fig. 6B).              HeLa cells transiently transfected siRNA nucleo-
   data imply localization Bcl-xL mem-          tides targeting Bcl-xL Mcl-1 prior treatment branes appears dispensable promote effects          ABT-737. Knockdown Mcl-1 enhanced specific response
terphenyl 14. imply Bcl-xL-dependent induction        ABT-737 (Fig. 7D). Importantly, stable Bax knockdown cell death terphenyl 14 unlikely rely process       HeLa cells (pSilencer Bax cells described  signifi- compound causes Bcl-xL expose BH3             cantly sensitive ABT-737 treatment Mcl-1 
domain. contrast, BH3-binding activity Bcl-xL appears      regulation control cells (Fig. 7E), indicating Bax play essential role. Consistent  microinjected       contributes,  induction cell death ABT-
wild-type Bcl-xL Bcl-xL G138A restored sensitivity       737-treated, Mcl-1-depleted HeLa cells. Cell death rates spe- Bcl-xL knockdown (pSilencer Bcl-xL) HeLa cells terphe-         cifically induced ABT-737 treatment Mcl-1-depleted cells
nyl 14-induced cell death (Fig. 6C). im-          reduced Bcl-xL expression coincidentally 
mortalized mouse embryonic fibroblasts derived mice          regulated (Fig. 7D). Knockdown Bcl-xL expression Bcl-xL genetically eliminated (Bcl-xâ«º/â«º               approach promoted resistance HeLa cells specific
MEFS) resistant terphenyl 14 treatment             effects terphenyl 14 (Fig. 7D).  like induced control MEFs (Fig. 6D). Wild-type Bcl-xL Bcl-xL              terphenyl 14, cell death induced ABT-737 combined G138A overcame resistance Bcl-xâ«º/â«º MEFS terphe-            Mcl-1 downregulation partly Bcl-xL dependent.
nyl 14 treatment (Fig. 6E).
   ABT-737 promotes Bcl-xL-dependent Bax activation.                                     DISCUSSION investigated BH3 mimetic molecules terphenyl 14 trigger Bcl-xL-dependent Bax activation using              recent observation neutralization antiapoptotic
ABT-737.                                                             Bcl-2 members suffice allow Bax-mediated apoptosis
   performed cell-free immunoprecipitation assays        (42) suggests healthy cells, involvement IVTR Bax presence absence recombinant Bcl-xL         BH3 activators, proportion Bax molecules exist described (Fig. 7A). ABT-737 released IVTR Bax            â€œprimedâ€? state, complexed prosurvival proteins Bcl-xL, judged presence, unbound fraction     Bcl-xL (1). results consistent view treatment, IVTR Bax immunoprecipitated              imply Bcl-xL itself contributes induction 2D2 anti-Bax antibody. molecules undergone               maintenance activated â€œprimedâ€? state Bax, change conformation immunoreacted 6A7            endogenous Bcl-xL allows terphenyl 14 unleash ac-
antibody. Terphenyl 14, reported  peptides           tive Bax permeabilize mitochondria kill cells. cell-
compassing BH3 domains Bad Bax  interfere           free assays cellular assays using variants Bcl-xL Bax Bcl-xL interactions [4]) released active Bax mol-      described indicate exposure BH3
 840      GAUTIER ET AL.                                                                                                               MOL. CELL. BIOL.




   FIG. 6. Bcl-xL G138A mutant does cooperate terphenyl 14.  B) Transiently transfected Bcl-xL G138A does restore sensitivity Bcl-xL knockdown HeLa cells   HCT116 p21â«º/â«º Pumaâ«º/â«º cells (B) terphenyl 14. Cells infected shBcl-xL
lentivirus prior transfection plasmids expressing shRNA-resistant cDNAs encoding indicated Bcl-xL variant vector treatment terphenyl 14 (100 â?®M). Death rates resulting cells evaluated 24 h later. Data means (â«¾ SE) results independent experiments. (Right) Western blot analysis Bcl-xL expression performed assess efficiency RNA interference
(using cells infected control lentivirus, Scr, positive control) transduction condition. â?¤-Tub., â?¤-tubulin. (C) Microinjection recombinant Bcl-xL G138A does restore sensitivity Bcl-xL knockdown HeLa cells terphenyl 14. Recombinant GST, GST-Bcl-xL, GST-Bcl-xL G138A (1 â?®M) microinjected fluorescent marker FITC-Dextran 40S (0.5 ) indicated HeLa cells 6 h
prior treatment terphenyl 14. percentage microinjected  e., fluorescent) cells exhibiting morphological features cell death assayed 18 h later. Data means (â«¾ SE) results independent experiments. (D) Resistance Bcl-xLâ«º/â«º cells terphenyl 14. Wild-type Bcl-xLâ«º/â«º MEFs treated terphenyl 14 (100 â?®M) DMSO carrier 18 h. activation DEVDase
   U., arbitrary units) loss cell viability   following treatment assayed. Data means (â«¾ SEM) results 3 independent experiments. (E) Transiently transfected Bcl-xL Bcl-xL G138A cooperates terphenyl 14 promote cell death Bcl-xL
knockout mouse embryonic fibroblasts. Bcl-xâ«º/â«º MEFs transfected indicated plasmids plasmid encoding red
fluorescent protein (RFP) DsRed transfection marker treated terphenyl 14 18 h prior morphological analysis fluorescent
cells. Data means (â«¾ SE) results independent experiments. P values assessed using Student t test.




domain Bcl-xL unlikely involved membrane                     xL, released active form inhibition BH3-
localization Bcl-xL dispensable, BH3 binding interface               binding activity Bcl-xL. protein crucial process. data strongly               currently know â€œtrap releaseâ€?
support notion Bcl-xL dependency terphenyl 14                  process extends multidomain Bcl-2 family members.
activity depends process Bax, â€œtrappedâ€? Bcl-                   resistance Bcl-xL knockout cells terphenyl 14  VOL. 31, 2011                                                                  ACTIVATION Bax RELEASE Bcl-XL                       841




   FIG. 7. ABT-737 promotes Bcl-xL-dependent Bax activation.   ABT-737 impacts Bax conformation presence Bcl-xL cell-free
assays.  35S-Bax bound recombinant Bcl-xL treated terphenyl 14 (10 â?®M), ABT-737 (1 â?®M), indicated BH3 peptides. resulting â€œfreeâ€? Bax molecules immunoprecipitated 2D2 6A7 anti-Bax antibody.  35S-Bax directly treated indicated compounds peptides absence Bcl-xL prior immunoprecipitation. (B) Expression Bax Bcl-xL renders yeast cells
sensitive ABT-737. effect 6-h ABT-737 treatment (20 â?®M) Bax/Bcl-xL interactions evaluated quantified described legend Fig. 4A B. Data means (â«¾ SE) results independent experiments. effect treatment viability yeast cells expressing indicated protein evaluated described legend Fig. 4C. Data means (â«¾ SEM) results 8
independent experiments. P values (â´±, P â¬? 0.005) assessed using Student t test. (C) Ectopic expression Bax sensitizes HeLa cells ABT-737 Bcl-xL-dependent process. HeLa cells infected indicated lentivirus, described legend Fig. 6A, transfected indicated plasmids, treated ABT-737 (5 â?®M) 18 h prior evaluation cell death. Data means (â«¾ SEM) results 3 independent experiments. insert, Western blot analysis Bax expression performed assess transduction efficiency condition. (D) Acute knockdown Bcl-xL mitigates cell death induced ABT-737 combination Mcl-1 downregulation. HeLa cells transfected indicated sequence siRNA prior treatment ABT-737 (1 â?®M), terphenyl 14 (100 â?®M), vehicle additional 24 h, loss cell viability evaluated. Cell death rates induced combination siRNA absence treatment represented white, specific cell death rates observed presence compound shown gray black  ABT-737 terphenyl 14, respectively). Data means (â«¾ SE) results independent experiments. Note death rates measured untreated
siCtr/siCtr siBcl-xL/siCtr cells shown twice, ABT-737 terphenyl 14-induced death rates, respectively. shows
representative Western blotting, confirming specificity RNA interference approach targeting Bcl-xL Mcl-1 expression. (E) Knock- Bax mitigates cell death induced ABT-737 combination Mcl-1 downregulation. Control (Scr) Bax knockdown (shBax,
expressing pSilencer Bax) HeLa cells transfected control siRNA (siCtr) siMcl-1 nucleotides 24 h treatment additional 24 h ABT-737 (1 â?®M) vehicle  followed evaluation loss cell viability. Data (represented panel D) means
(â«¾ SE) results independent experiments.




incomplete, implying targets involved               recapitulates ability Bcl-xL release active Bax  biological effects compound. Terphenyl 14 inhibits             sponse sensitizer BH3 peptides cell-free assays (4). BH3-binding activity Bcl-xL              noteworthy Bax played major role Mcl-1 Bcl-2 (data shown), protein                apoptotic responses studied  present work  842     GAUTIER ET AL.                                                                                                  MOL. CELL. BIOL.


investigate Bcl-xL inhibition recruit activity proapoptotic multidomain protein, Bak.
   findings imply inhibition direct interaction Bcl-xL Bax launch Bax-dependent apoptotic
program absence direct, highly efficient BH3
activators. best exemplified experiments 
formed yeast.  demonstrated Bcl-xL-depen-
dent induction mammalian apoptosis terphenyl com-
pound using mammalian cells harbor constitutive
BH3 activator-related death signals render Bcl-xL neces-
sary maintain viability  tolerate Bcl-xL downregu-
lation) mammalian cells tolerance Bcl-xL deple-
tion induced precisely knocking expression activator BH3 protein, involved rendering
Bcl-xL acutely necessary survival cells (HCT116
p21â«º/â«º Pumaâ«º/â«º). fact BH3 activators dispens-
able triggering cell death signals sole displace-
ment Bax Bcl-xL supported observation terphenyl 14, triggers Bcl-xL Bax-dependent
cell death, unable recruit Puma displacing Bcl-xL cell configuration. lack effect 
trasts ability terphenyl compound compete binding diverse BH3 peptides (including Puma) Bcl-xL cell-free assays. speculate rely fact kon rate koff rate (kon koff,
association dissociation rate constants, respectively) terphenyl 14 binding Bcl-xL compound efficiently compete Puma create free Puma
proteins. note, preferential displacement Bax         FIG. 8. Model Bax activation interaction Puma stem,  difference             release Bcl-xL. Mitoch., mitochondrial. text details.
binding affinities Bax-BH3 versus Puma-BH3 Bcl-xL measured higher affinity Puma-BH3 peptide (41
nM) Bax-BH3 peptide (147 nM) Bcl-xL, using            sufficient Bax induction apoptosis (12). fluorescence polarization (data shown).                           suggest Bcl-xL permits conformational change native
   data dispute fact Bcl-xL exerts anti-      Bax engaging BH3 domain. Additional regions, distinct
apoptotic activity sequestering BH3 activators Bax itself.      constitute Bcl-xL BH3 binding site sensu unravel Bcl-xL interaction Bax shifts          stricto, involved initial interactions bringing
equilibrium activated conformation Bax.             conformational change (Fig. 8A). Alternatively, nature interaction primes Bax maintains      Bcl-xL bind Bax molecules open BH3 domain
active conformation, sustained Bcl-xL activity         arise nonfavored equilibrium absence
particular, sustained binding Bax) required survival.       acute stress (Fig. 8B). case, Bcl-xL maintain process, certain cancer cells â€œaddictedâ€?       â€œopenâ€? Bax molecules bound state preserve viability Bcl-xL absence  direct Bax-activating       time favors existence â€œprimedâ€? Bax
signals. â€œaddictiveâ€? effects Bcl-2 Bcl-xL        molecules  BH3 domain exposed). Disruption reported, relying shift energy metabolism           Bcl-xL/Bax complexes unleash free, membrane 
oxidative phosphorylation glycolysis Bcl-xL overex-           sertion-competent Bax molecules initiate cell death. Fur-
pression (35) enhancing effect Bcl-2 expres-       ther feed-forward mechanisms intervene, relatively
sion proapoptotic proteins (27). addictive process          small amounts active Bax molecules suffice initiate differs mechanistically    cell death (20) (48). ability Bcl-xL engage BH3-domain-dependent               model implies BH3 mimetic molecules teraction Bax, e., property prosurvival       terphenyl 14 trigger Bcl-xL-dependent Bax activa-
activity relies, involved.                                   tion, fact ABT-737 uses Bcl-xL certain instances    Bax activated â€œtrap releaseâ€? mechanism?          promote Bax-dependent cell death particularly significant. Bax activated perturbation multiple           feature apparent Mcl-1 expression downregu-
sites (44), speculate Bcl-xL sustains process         lated, Bcl-xL-dependent induction cell death facilitating exposure BH3 domain Bax, bur-         terphenyl 14 detected presence Mcl-1 ied inside native Bax. Exposure Bax BH3 domain              cellular context (Fig. 7). difference likely stem
understood accompany general disruption hydro-            fact terphenyl 14 counteract ability phobic core native Bax formed helixes â?£1, â?£4, â?£5, â?£6        Mcl-1 prevent apoptosis. ABT-737 differs terphe-
(36) facilitate Bax homo-oligomerization (46),           nyl 14 efficiently binds BH3-binding
 VOL. 31, 2011                                                                             ACTIVATION Bax RELEASE Bcl-XL                                   843


interface Bcl-xL. speculate prolonged treat-                           5. Cartron, P. F., L. Oliver, E. Mayat, K. Meflah, F. M. Vallette. 2004.
                                                                                          Impact pH Bax alpha conformation, oligomerisation mitochon-
ment ABT-737, property paradoxically mitigate                             drial integration. FEBS Lett. 578:41â€“46. â€œtrap releaseâ€? process preventing novo formation                         6. Cartron, P. F., et al. 2003. N-terminal end Bax contains mitochon- Bax/Bcl-xL complexes. Reciprocally, Bcl-xL-dependent                               drial-targeting signal. J. Biol. Chem. 278:11633â€“11641.
                                                                                       7. Chang, B. S., et al. 1999. BH3 domain Bcl-x(S) required process manifest disruption existing                                inhibition antiapoptotic function Bcl-x(L). Mol. Cell. Biol. 9:6673â€“
complexes prevails inhibition complex formation.                               6681.
observed cycloheximide enhances sensitivity HeLa                           8. Chipuk, J. E., et al. 2008. Mechanism apoptosis induction inhibition                                                                                           anti-apoptotic BCL-2 proteins. Proc. Natl. Acad. Sci. U. S.  105:20327â€“
cells induction death ABT-737 Bcl-xL-dependent                              20332.
manner (data shown). result specific                             9. Del Gaizo Moore, V., et al. 2007. Chronic lymphocytic leukemia requires
effect expression short-lived Mcl-1                               BCL2 sequester prodeath BIM, explaining sensitivity BCL2 antagonist
                                                                                          ABT-737. J. Clin. Invest. 117:112â€“121.
additional consequences novo protein synthesis inhibi-                          10. Desagher, S., et al. 1999. Bid-induced conformational change Bax tion.                                                                                     responsible mitochondrial cytochrome c release apoptosis. J. Cell
                                                                                          Biol. 144:891â€“901.
   ABT-737 displaces Bax antiapoptotic tar-
                                                                                      11. Gallenne, T., et al. 2009. Bax activation BH3 protein Puma
gets BH3 activators Bim Puma,                                 promotes cell dependence antiapoptotic Bcl-2 family members. J. Cell
recruiting ability activate Bax induce efficient cell                         Biol. 185:279â€“290.
                                                                                      12. George, N. M., J. J. Evans, X. Luo. 2007. helix homo-oligomer-
death  reference 24). observations hinted                                ization domain containing BH3 BH1 responsible apoptotic parameters sole displacement BH3 ac-                               activity Bax. Genes Dev. 21:1937â€“1948.
tivators Bcl-2 homologues intervene:   sensitivity                       13. Gillissen, B., et al. 2003. Induction cell death BH3 Bcl-2
                                                                                          homolog Nbk/Bik mediated entirely Bax-dependent mitochondrial ABT-737 suggested rely ability disrupt Bcl-2                          pathway. EMBO J. 22:3580â€“3590.
interactions Bax itself (17); (ii) overexpression Bcl-xL                      14. Green, D. R., G. Kroemer. 2004. pathophysiology mitochondrial
does promote resistance ABT-737 (35); (iii) resis-                            cell death. Science 305:626â€“629.
                                                                                      15. Hsu, Y. T., K. G. Wolter, R. J. Youle. 1997. Cytosol membrane
tance small-cell lung cancer cell lines ABT-737 coincides                           redistribution Bax Bcl-X(L) apoptosis. Proc. Natl. Acad. Sci. low expression Bim high expression Mcl-1                               U. S.  94:3668â€“3672. low expression Bcl-2 Bcl-xL (37). results                        16. Kim, H., et al. 2006. Hierarchical regulation mitochondrion-dependent
                                                                                          apoptosis BCL-2 subfamilies. Nat. Cell Biol. 8:1348â€“1358.
imply disruption complexes Bax Bcl-xL                         17. Konopleva, M., et al. 2006. Mechanisms apoptosis sensitivity resis- additional parameter contributes sensitivity                            tance BH3 mimetic ABT-737 acute myeloid leukemia. Cancer Cell
ABT-737 clinical efficiency analogous com-                             10:375â€“388.
                                                                                      18. Kutzki, O., et al. 2002. Development potent Bcl-x(L) antagonist based
pounds, oral version ABT-737, ABT-263,                              alpha-helix mimicry. J.  Chem. Soc. 124:11838â€“11839. entered clinical trials. general perspec-                       19. Kuwana, T., et al. 2002. Bid, Bax, lipids cooperate form supramo-
                                                                                          lecular openings outer mitochondrial membrane. Cell 111:331â€“342.
tive, data imply cancer cell response given                         20. Lakhani, S. , et al. 2006. Caspases 3 7: key mediators mitochondrial
Bcl-xL inhibitor relies nature interactions                              events apoptosis. Science 311:847â€“851.
gaged Bcl-xL nature interactions                         21. Lalier, L., et al. 2007. Bax activation mitochondrial insertion                                                                                           apoptosis. Apoptosis 12:887â€“896.
inhibitor disrupt. â€œFreeâ€? Bcl-xL molecules correlate                         22. Letai,  2009. Puma strikes Bax. J. Cell Biol. 185:189â€“191. resistance, molecules occupied BH3 activators                             23. Letai, , et al. 2002. Distinct BH3 domains sensitize activate Bax itself correlate sensitivity. Understanding                          mitochondrial apoptosis, serving prototype cancer therapeutics. Cancer
                                                                                          Cell 2:183â€“192. interactions Bcl-xL BH3 activators                           24. Letai,  G. 2008. Diagnosing exploiting cancerâ€™s addiction blocks Bax regulated cancer cells  particular,                            apoptosis. Nat. Rev. Cancer 8:121â€“132.
impact  crucial understanding                        25. Maiuri, M. C., et al. 2007. Functional physical interaction                                                                                           Bcl-X(L) BH3-like domain Beclin-1. EMBO J. 26:2527â€“2539. molecular mechanisms Bcl-xL contributes aber-                            26. Manero, F., et al. 2006. small organic compound HA14-1 prevents Bcl-2
rant survival cells.                                                             interaction Bax sensitize malignant glioma cells induction cell
                                                                                          death. Cancer Res. 66:2757â€“2764.
                                                                                      27. Mitsiades, C. S., et al. 2007. Bcl-2 overexpression thyroid carcinoma cells
                         ACKNOWLEDGMENTS                                                  increases sensitivity Bcl-2 homology 3 domain inhibition. J. Clin. Endo-
                                                                                          crinol. Metab. 92:4845â€“4852.
  feel indebted Muriel Priault generous sharing                      28. Moreau, C., et al. 2003. Minimal BH3 peptides promote cell death reagents advice. thank David Huang gift                         antagonizing anti-apoptotic proteins. J. Biol. Chem. 278:19426â€“19435.
wild-type Bcl-xL knockout MEFs Jean Claude Martinou                       29. Muchmore, S. W., et al. 1996. X-ray NMR structure human Bcl-xL, tagged recombinant proteins. thank Lisa Oliver fruitful                        inhibitor programmed cell death. Nature 381:335â€“341.
comments.                                                                             30. Oltersdorf, T., et al. 2005. inhibitor Bcl-2 family proteins induces
  P.J. supported ARC   4895), Fondation France (Tumor                         regression solid tumours. Nature 435:677â€“681.
Committee), gion Pays la Loire (CIMATH network), Insti-                     31. Ottilie, S., et al. 1997. Structural functional complementation                                                                                           inactive Bcl-2 mutant Bax truncation. J. Biol. Chem. 272:16955â€“16961.
tut Recherche Servier.
                                                                                      32. Petros,  M., E. T. Olejniczak, S. W. Fesik. 2004. Structural biology                                                                                           Bcl-2 family proteins. Biochim. Biophys. Acta 1644:83â€“94.
                                REFERENCES                                            33. Priault, M., et al. 2003. Investigation role C-terminus Bax 1. Adams, J. M., S. Cory. 2007. Bcl-2 apoptotic switch cancer                  tc-Bid Bax interaction yeast mitochondria. Cell Death Differ.
   development therapy. Oncogene 26:1324â€“1337.                                        10:1068â€“1077.
2. Amundson, S. , et al. 2000. informatics approach identifying markers       34. Reed, J. C. 2003. Apoptosis-targeted therapies cancer. Cancer Cell
   chemosensitivity human cancer cell lines. Cancer Res. 60:6101â€“6110.                 3:17â€“22.
3. Arokium, H., N. Camougrand, F. M. Vallette, S. Manon. 2004. Studies            35. Schwartz, P. S., et al. 2007. 2-Methoxy antimycin reveals unique mecha-
   interaction substituted mutants BAX yeast mitochondria               nism Bcl-x(L) inhibition. Mol. Cancer Ther. 6:2073â€“2080.
   reveal C-terminal hydrophobic alpha-helix second ART se-             36. Suzuki, M., R. J. Youle, N. Tjandra. 2000. Structure Bax: coregulation
   quence plays role interaction anti-apoptotic BCL-xL.                 dimer formation intracellular localization. Cell 103:645â€“654.
   J. Biol. Chem. 279:52566â€“52573.                                                    37. Tahir, S. K., et al. 2007. Influence Bcl-2 family members cellular
4. Cartron, P. F., et al. 2004. alpha helix Bax plays necessary role       response small-cell lung cancer cell lines ABT-737. Cancer Res. 67:
   ligand-induced activation BH3 proteins Bid PUMA.                1176â€“1183.
   Mol. Cell 16:807â€“818.                                                              38. Terradillos, O., S. Montessuit, D. C. Huang, J. C. Martinou. 2002.
 844         GAUTIER ET AL.                                                                                                                              MOL. CELL. BIOL.

      Direct addition BimL mitochondria does lead cytochrome c                    low-molecular-weight antagonists Bcl-xL. J.  Chem. Soc.
      release. FEBS Lett. 522:29â€“34.                                                           127:10191â€“10196.
39.   Tremblais, K., et al. 1999. C-terminus bax membrane                44.   Youle, R. J.,  Strasser. 2008. BCL-2 protein family: opposing
      addressing/anchoring signal. Biochem. Biophys. Res. Commun. 260:582â€“                     activities mediate cell death. Nat. Rev. Mol. Cell Biol. 9:47â€“59.
      591.                                                 